| 臺大學術典藏 |
2022-01-13T08:46:00Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; PO-JEN YANG; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; Kao J.-H.; Yang W.-S. |
| 臺大學術典藏 |
2022-01-07T06:05:52Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; CHIH-YUAN LEE; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 國立成功大學 |
2022 |
Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents
|
Huang, S.-C.;Cheng, P.-N.;Liu, C.-H.;Yang, H.-C.;Su, T.-H.;Tseng, Tseng T.-C.;Chen, P.-J.;Kao, J.-H.;Liu, C.-J. |
| 臺大學術典藏 |
2021-12-01T02:29:06Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
|
Liu C.-H.; Liu C.-J.; CHIEN-CHING HUNG; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-10-27T03:22:18Z |
Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era
|
Cheng C.-L.; Huang S.-C.; Chen J.-H.; Wei C.-H.; Fang W.-Q.; Su T.-H.; CHANG-TSU YUAN; Liu J.-H.; Chuang M.-K.; Tien H.-F. |
| 臺大學術典藏 |
2021-09-27T05:32:39Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; Sun H.-Y.; Hsieh S.-M.; Liu W.-C.; WANG-HUEI SHENG; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T06:12:40Z |
APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers [5]
|
Su T.-H.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:33Z |
Acute fatty liver of pregnancy with concurrent acute hepatitis B virus infection
|
Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:18Z |
Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B
|
Su T.-H.; Hsu C.-S.; Chen C.-L.; Liu C.-H.; Huang Y.-W.; Tseng T.-C.; Liu C.-J.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:14Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; JIA-HORNG KAO; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:09Z |
The clinical significance of occult hepatitis B transfusion in Taiwan - a look-back study
|
Su T.-H.; Chen P.-J.; Chen T.-C.; Cheng H.-R.; Li L.; Lin K.-S.; JIA-HORNG KAO; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:12:03Z |
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load
|
Tseng T.-C.; Liu C.-J.; Yang H.-C.; Su T.-H.; Wang C.-C.; Chen C.-L.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:02Z |
Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters
|
Tseng T.-C.; Liu C.-J.; Chen C.-L.; Wang C.-C.; Su T.-H.; Kuo S.F.-T.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:01Z |
Host genetic variants and hepatitis b virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission
|
Lin C.-L.; Tseng T.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load
|
Tseng T.-C.; Liu C.-J.; Yang H.-C.; Su T.-H.; Wang C.-C.; Chen C.-L.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:55Z |
Young chronic hepatitis b patients with nucleos(t)ide analogue-induced hepatitis b e antigen seroconversion have a higher risk of HBV reactivation
|
Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang H.-C.; Wang C.-C.; Chen C.-L.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:54Z |
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
|
Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Hsu C.-S.; Lin H.H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:52Z |
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
|
Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; Su T.-H.; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:51Z |
Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads
|
Tseng T.-C.; Liu C.-J.; Yang H.-C.; Su T.-H.; Wang C.-C.; Chen C.-L.; Hsu C.-A.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:51Z |
Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients
|
Cheng H.-R.; Liu C.-J.; Tseng T.-C.; Su T.-H.; Yang H.-I.; Chen C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:50Z |
Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection
|
Su T.-H.; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen C.-L.; Chen P.-J.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:49Z |
Milder clinical manifestation of scrub typhus in Kinmen, Taiwan
|
Su T.-H.; Liu C.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:48Z |
Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C
|
Su T.-H.; Liu C.-H.; Liu C.-J.; Chen C.-L.; Ting T.-T.; Tseng T.-C.; Chen P.-J.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:45Z |
Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers
|
Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Yang W.-T.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:44Z |
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:43Z |
Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy
|
Su T.-H.; Liu C.-J.; Yang H.-C.; Jeng Y.-M.; Cheng H.-R.; Liu C.-H.; Tseng T.-C.; Ling T.-Y.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:42Z |
Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin
|
Chen M.-Y.; Liu C.-H.; Chen T.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:41Z |
Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters
|
Tseng T.-C.; Liu C.-J.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:40Z |
Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications
|
Wu H.-L.; JIA-HORNG KAO; Chen T.-C.; Wu W.-H.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen D.-S.; Chen P.-J.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:40Z |
Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously
|
Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Chen T.-C.; Tseng T.-C.; Liu C.-H.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:37Z |
Molecular mechanism and treatment of viral hepatitis-related liver fibrosis
|
Su T.-H.; JIA-HORNG KAO; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:32Z |
Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B
|
Lin C.-L.; Liu C.-H.; Wang C.-C.; Liang C.-C.; Su T.-H.; Liu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:30Z |
Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
|
Chen G.-Y.; Su T.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:30Z |
Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection
|
Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:29Z |
Improving clinical outcomes of chronic hepatitis B virus infection
|
Su T.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:28Z |
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
|
Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:27Z |
Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:27Z |
Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy
|
Liang C.-C.; Liu C.-H.; Chung C.-S.; Lin C.-K.; Su T.-H.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:27Z |
Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection
|
Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang W.-T.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:25Z |
Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:25Z |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
|
Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:23Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:23Z |
Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers
|
Tseng T.-C.; Liu C.-J.; Yang H.-C.; Chen C.-L.; Yang W.-T.; Tsai C.-S.; Kuo S.F.-T.; Verbree F.C.; Su T.-H.; Wang C.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:22Z |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:21Z |
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
|
Liu C.-H.; Sheng W.-H.; Sun H.-Y.; Hsieh S.-M.; Lo Y.-C.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu W.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:20Z |
Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model
|
Li Y.-T.; Liu C.-J.; Su T.-H.; Cheng H.-R.; Jeng Y.-M.; Lin H.-L.; Wang C.-C.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.; Wu H.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:20Z |
Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis
|
Yang H.-I.; Tseng T.-C.; Liu J.; Lee M.-H.; Liu C.-J.; Su T.-H.; Batrla-Utermann R.; Chan H.L.Y.; JIA-HORNG KAO; Chen C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; Su T.-H.; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; JIA-HORNG KAO |
